SCHEMBL1681004

SCHEMBL1681004

CCCC(O)C(=O)N(C)C

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRM1 P11229 1/20 0.39
AKR1A1 P14550 1/20 0.39
CHRM3 P20309 1/20 0.39
HTR2A P28223 1/20 0.39
HTR2C P28335 1/20 0.39
ADRA1A P35348 1/20 0.39
HRH1 P35367 1/20 0.39
DRD3 P35462 1/20 0.39
SLC6A3 Q01959 1/20 0.39
HDAC1 Q13547 1/20 0.39
HDAC2 Q92769 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
CYP3A4 P08684 2/20 0.37
TSHR P16473 2/20 0.37
NFKB1 P19838 2/20 0.37
NPSR1 Q6W5P4 2/20 0.37
GPR84 Q9NQS5 3/20 0.37
FFAR1 O14842 1/20 0.37
ALDH1A1 P00352 1/20 0.36
HDAC7 Q8WUI4 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1681272 0.86 GPR84 (0.48) GPR84FFAR1ALDH1A1PDF
SCHEMBL20640480 0.82 GPR84 (0.61) GPR84FFAR1
SCHEMBL4072000 0.79
SCHEMBL27476663 0.78 CA12 (0.44) CHRM1AKR1A1CHRM3HTR2AHTR2C
SCHEMBL17144449 0.78 GABRR1 (0.39)
SCHEMBL3074236 0.78 GABRR1 (0.39)
SCHEMBL5004177 0.78 CA12 (0.44) CHRM1AKR1A1CHRM3HTR2AHTR2C
SCHEMBL5518357 0.77 HDAC1 (0.52) CHRM1AKR1A1CHRM3HTR2AHTR2C
SCHEMBL11494381 0.76 GPR84 (0.34) GPR84FFAR1
SCHEMBL15314113 0.75 CHRM1 (0.39) CHRM1AKR1A1CHRM3HTR2AHTR2C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2491008-B1 ETHER-AMIDE COMPOUNDS AND USES THEREOF RHODIA OPERATIONS (FR) 2019-08-21 EP disclosed
EP-2491008-B1 ETHER-AMIDE COMPOUNDS AND USES THEREOF RHODIA OPERATIONS (FR) 2019-08-21 EP disclosed
US-8981150-B2 Ether-amide compounds and uses thereof RHODIA OPERATIONS (FR) 2015-03-17 US disclosed
US-8981150-B2 Ether-amide compounds and uses thereof RHODIA OPERATIONS (FR) 2015-03-17 US disclosed
US-8981150-B2 Ether-amide compounds and uses thereof RHODIA OPERATIONS (FR) 2015-03-17 US disclosed
US-20120302791-A1 ETHER-AMIDE COMPOUNDS AND USES THEREOF SPECIALTY OPERATIONS FRANCE (FR) 2012-11-29 US disclosed
EP-2491008-A1 ETHER-AMIDE COMPOUNDS AND USES THEREOF Rhodia Operations (FR) 2012-08-29 EP disclosed
WO-2011106168-A1 PURINE COMPOUNDS FOR TREATING AUTOIMMUNE AND DEMYELINATING DISEASES DCAM PHARMA INC (US) 2011-09-01 WO disclosed
WO-2011048314-A1 ETHER-AMIDE COMPOUNDS AND USES THEREOF RHODIA OPERATIONS (FR) 2011-04-28 WO disclosed
WO-2011048314-A1 ETHER-AMIDE COMPOUNDS AND USES THEREOF RHODIA OPERATIONS (FR) 2011-04-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120302791-A1 ETHER-AMIDE COMPOUNDS AND USES THEREOF NAPEPLD, AGPAT2, PNN CHRM1 4583/4885AKR1A1 2409/4885CHRM3 4237/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.